GH Research PLC (GHRS) stock: key figures, P/E, revenue and dividend
Health Care · Ireland · ISIN IE000GID8VI0
GH Research PLC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Gross profit | 0.00 USD |
| Operating income | -60.72 m USD |
| EBIT | -60.00 m USD |
| Net income | -48.26 m USD |
| Diluted EPS – continuing operations | -0.78 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
More stocks
- Caltagirone SpA (CALT.MI)
- DEL MONTE CORP (DMC)
- Nagacorp Ltd (3918.HK)
- Hong Leong Industries Bhd (3301.KL)
- Adtran Networks (ADV.DE)
- Nsfocus Information Technology Co Ltd (300369.SZ)
- Tyra Biosciences, Inc. (TYRA)
- HawkEye 360, Inc. (HAWK)
- LA-Z-BOY INC (LZB)
- Hainan Haide Industry Co Ltd (000567.SZ)
- Taiwan FamilyMart Co Ltd (5903.TWO)
- GoodRx Holdings, Inc. (GDRX)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.